1. Home
  2. SCOR vs CGTX Comparison

SCOR vs CGTX Comparison

Compare SCOR & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo comScore Inc.

SCOR

comScore Inc.

HOLD

Current Price

$6.51

Market Cap

112.4M

ML Signal

HOLD

Logo Cognition Therapeutics Inc.

CGTX

Cognition Therapeutics Inc.

HOLD

Current Price

$1.15

Market Cap

110.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCOR
CGTX
Founded
1999
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
112.4M
110.8M
IPO Year
2007
2021

Fundamental Metrics

Financial Performance
Metric
SCOR
CGTX
Price
$6.51
$1.15
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$3.33
AVG Volume (30 Days)
10.9K
979.8K
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
127.37
62.79
EPS
4.25
N/A
Revenue
$403,549,000.00
N/A
Revenue This Year
$2.75
N/A
Revenue Next Year
$7.30
N/A
P/E Ratio
$1.65
N/A
Revenue Growth
1.02
N/A
52 Week Low
$4.39
$0.22
52 Week High
$10.18
$3.83

Technical Indicators

Market Signals
Indicator
SCOR
CGTX
Relative Strength Index (RSI) 38.39 48.73
Support Level $6.28 $1.01
Resistance Level $7.07 $1.19
Average True Range (ATR) 0.43 0.09
MACD -0.08 -0.02
Stochastic Oscillator 10.10 17.02

Price Performance

Historical Comparison
SCOR
CGTX

About SCOR comScore Inc.

comScore Inc is a information and analytics company that measures advertising, content, and the consumer audiences of each, across media platforms. It create products using a data platform that combines information on digital platforms (connected televisions, mobile devices, tablets and computers), televisions, direct to consumer applications, and movie screens with demographics and other descriptive information. The company has developed proprietary data science that enables measurement of person-level and household-level audiences, removing duplicated viewing across devices and over time. Its segments include Content & Ad Measurement and Research & Insight Solutions of which the Content & Ad Measurement segment derives the majority of the revenue.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).

Share on Social Networks: